Nanoparticle-based strategies for cancer immunotherapy and immunodiagnostics

Immunotherapy

Novel immunotherapy strategies for hepatobiliary cancers

Immunotherapy.

DeLeon TT, Zhou Y, Nagalo BM, Yokoda RT, Ahn DH, Ramanathan RK, Salomao MA, Aqel BA, Mahipal A, Bekaii-Saab TS, Borad MJ

doi: 10.2217/imt-2018-0024.

Immunotherapy

Immunotherapy in Gastrointestinal Cancers

Biomed Res Int.

Procaccio L, Schirripa M, Fassan M, Vecchione L, Bergamo F, Prete AA, Intini R, Manai C, Dadduzio V, Boscolo A, Zagonel V, Lonardi S

doi: 10.1155/2017/4346576.

Melanoma and Skin Cancer

Effective cancer immunotherapy based on combination of TLR agonists with stimulation of phagocytosis

Int Immunopharmacol.

Caisová V, Uher O, Nedbalová P, Jochmanová I, Kvardová K, Masáková K, Krejčová G, Paďouková L, Chmelař J, Kopecký J, Ženka J

doi: 10.1016/

Melanoma and Skin CancerImmunotherapy

Identification of essential genes for cancer immunotherapy

Nature.

Patel SJ, Sanjana NE, Kishton RJ, Eidizadeh A, Vodnala SK, Cam M, Gartner JJ, Jia L, Steinberg SM, Yamamoto TN, Merchant AS, Mehta GU, Chichura A, Shalem O, Tran E, Eil R, Sukumar M, Guijarro EP, Day CP, Robbins P, Feldman S, Merlino G, Zhang F, Restifo NP

doi: 10.1038/nature23477.

Melanoma and Skin CancerImmunotherapy

Polymeric nanoparticles encapsulating novel TLR7/8 agonists as immunostimulatory adjuvants for enhanced cancer immunotherapy

Biomaterials

Kim H, Niu L, Larson P, Kucaba TA, Murphy KA, James BR, Ferguson DM, Griffith TS, Panyam J

doi: 10.1016/j.biomaterials.

RECOMMENDED

Immunotherapy

Development of a novel class of interleukin-2 immunotherapies for metastatic cancer

doi: smw.2019.14697.

Immunotherapy

Is autoimmunity the Achilles' heel of cancer immunotherapy?

Nat Med.

June CH, Warshauer JT, Bluestone JA

doi: 10.1038/nm.4321.

Critical features and challenges associated with imaging in patients undergoing cancer immunotherapy

Crit Rev Oncol Hematol.

Solinas C, Porcu M, Hlavata Z, De Silva P, Puzzoni M, Willard-Gallo K, Scartozzi M, Saba L

doi: 10.1016/

T Cells

Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis

Semin Cancer Biol.

Kumar P, Saini S, Prabhakar BS

doi: 10.1016/j.semcancer.

Related content

Novel immunotherapy strategies for hepatobiliary cancers

Immunotherapy in Gastrointestinal Cancers

Effective cancer immunotherapy based on combination of TLR agonists with stimulation of phagocytosis

Identification of essential genes for cancer immunotherapy

Polymeric nanoparticles encapsulating novel TLR7/8 agonists as immunostimulatory adjuvants for enhanced cancer immunotherapy

Development of a novel class of interleukin-2 immunotherapies for metastatic cancer

Is autoimmunity the Achilles' heel of cancer immunotherapy?

Critical features and challenges associated with imaging in patients undergoing cancer immunotherapy

Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis